Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005066 · ClinicalTrials.gov registry record · Phase 2
O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma
A Phase 2 study of Sarcoma, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 10
- Study locations
NCT00005066: Completed Phase 2 study of Sarcoma, sponsored by University of Chicago.
NCT00005066 is a Phase 2 study of Sarcoma that has completed, run by University of Chicago. The registered enrollment target is 12 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower). The trial reports 10 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005066, a Phase 2 study of Sarcoma, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 10
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining O6-benzylguanine and carmustine in treating patients who have recurrent, metastatic, or locally advanced soft tissue sarcoma.
Conditions Studied
Interventions
- DRUG O6-benzylguanine
- DRUG carmustine
Study Locations (10)
Illinois
- University of Illinois at Chicago - Chicago
- University of Chicago Cancer Research Center - Chicago
- Louis A. Weiss Memorial Hospital - Chicago
- Cancer Care Specialists of Central Illinois, S.C. - Decatur
- Evanston Northwestern Health Care - Evanston
- Division of Hematology/Oncology - Park Ridge
- Oncology/Hematology Associates of Central Illinois, P.C. - Peoria
- Central Illinois Hematology Oncology Center - Springfield
Indiana
- Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne
- Michiana Hematology/Oncology P.C. - South Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2000-06 |
| Est. Completion | 2002-10 |
| Phase | Phase 2 |
What the finished NCT00005066 record still lists
NCT00005066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which O6-benzylguanine is the first listed.
NCT00005066 lists 10 locations in 2 states (Illinois, Indiana).
Frequently Asked Questions
What is clinical trial NCT00005066 about?
NCT00005066 is a clinical study titled "O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining O6-benzylguanine and carmustine in treating patients who ha...
What is the current status of trial NCT00005066?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2000-06. Estimated completion is 2002-10.
What conditions does trial NCT00005066 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT00005066?
The interventions under investigation include: O6-benzylguanine (DRUG), carmustine (DRUG).
Who is sponsoring clinical trial NCT00005066?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005066 being conducted?
This trial has 10 study locations across Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00005066's enrollment target sits among peer trials
12 113th of 122 higher than 10 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia